et al.. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol (2021) 22(8):1151–61. doi: 10...
参考文献: [1] Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021 Aug;22(8):1151-1161. [2] Li Y, Abudurehei...
1.Miglietta Federica,Griguolo Gaia,Bottosso Michele et al. HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment.[J] .NPJ Breast Cancer, 2022, 8: 66.
[2]Schettini F,Chic N,Brasó-Maristany F,et al.Clinical,Pathological,and PAM50 Gene Expression Features of HER2-Low Breast Cancer.NPJ Breast Cancer(2021)7:1. [3]Denkert C,Seither F,Schneeweiss A,et al.Clinical and Molecular Characteristics of HER2-Low-Positive Breast Cancer:Pooled Analysis ...
Bottosso M, Giarratano T, Lo Mele M, Fassan M, Cacciatore M, Genovesi E, De Bartolo D, Vernaci G, Amato O, Porra F, Conte P, Guarneri V, Dieci MV. HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment. NPJ Breast Cancer. 2022;...
17.Denkert C, Seither F, Schneeweiss A, Link T, Blohmer JU, Just M, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021;22(8):1151–61. ...
Untch M, Loibl S. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021 Aug;22(8):1151-1161. doi: 10.1016/S1470-2045(21)00301-6. Epub 2021 Jul 9. PMID: 34...
3. Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials [published online ahead of print, 2021 Jul 9]. Lancet Oncol. 2021;S1470-2045...
[3] Jin J, et al. Analysis of clinical features, genomic landscapes and survivaloutcomes in HER2-low breast cancer. J Transl Med,2023;21(1):360. [4] Denkert C, et al. Clinical and molecular characteristics of HER2-low-positivebreast cancer: pooled analysis of individual patient data from...
HORMONE receptor positive breast cancerBREAST cancerANTIBODY-drug conjugatesBREAST tumorsTUMORSApproximately a half of breast tumors classified as HER2-negative exhibit HER2-low-positive expression. We recently described a high instability of HER2-low-positive expression from primary...